Year Published
- 2008 (0)
- 2009 (1) Apply 2009 filter
- 2010 (3) Apply 2010 filter
- (-) Remove 2011 filter 2011
- 2012 (0)
- 2013 (1) Apply 2013 filter
- 2014 (1) Apply 2014 filter
- 2015 (1) Apply 2015 filter
- 2016 (6) Apply 2016 filter
- 2017 (4) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (0)
- Literature Review (1) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (1) Apply Research Brief filter
Geography
- East Africa Region and Selected Countries (1) Apply East Africa Region and Selected Countries filter
- Global (1) Apply Global filter
- South Asia Region and Selected Countries (0)
- Southern Africa Region and Selected Countries (1) Apply Southern Africa Region and Selected Countries filter
- Sub-Saharan Africa (1) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (1) Apply West Africa Region and Selected Countries filter
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove Risk, Preferences, & Decision-Making filter Risk, Preferences, & Decision-Making
- (-) Remove Research & Development filter Research & Development
- (-) Remove 2011 filter 2011
- (-) Remove 2018 filter 2018
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
This brief presents selected material from the Fourth African Agricultural Markets Program (AAMP) policy symposium, Agricultural Risks Management in Africa: Taking Stock of What Has and Hasn’t Worked, organized by the Alliance for Commodity Trade in Eastern and Southern Africa and the Common Market for Eastern and Southern Africa that took place in Lilongwe, Malawi, September 6-10, 2010. We draw almost exclusively from Rashid and Jayne’s summary, “Risk Management in African Agriculture: A review of experiences.” This article summarizes across the background papers, with major findings grouped into three broad categories: cross cutting, government-led policies, and modern instruments.